RECRUITING

Alternation in the Human Microbiome With Commonly Used Topical Medications

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The global aim of this study is to investigate how the human microbiome changes from baseline with commonly used topical medications such as topical antifungals, low to mid potency topical steroids and emollients. The specific aims are as follows: 1. Investigate whether ketoconazole cream, a commonly used topical antifungal, causes alterations in the human skin microbiome with short-term use. 2. Investigate whether desonide 0.05 % ointment, a commonly used low potency topical steroid, alters the human microbiome with short-term use.

Official Title

Alterations in the Human Microbiome With Commonly Used Topical Medications

Quick Facts

Study Start:2013-01-28
Study Completion:2026-09-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03437005

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * Individuals with known chronically active skin diseases, including atopic dermatitis, psoriasis, seborrheic dermatitis, other autoimmune and inflammatory skin conditions.
  2. * Patients with a history of skin cancer, multiple nevi, or other isolated lesions will not be excluded.
  3. * Individuals who have used topical, intravenous, intramuscular, or oral antibiotics within the last 6 months
  4. * Individuals with known allergies to any of the study medications.
  5. * Individuals younger than 18 years of age.
  6. * Adults unable to consent
  7. * Non-English speaking individuals. Given the complexity in the instructions that subjects will need to follow for proper sample collection, we will not seek to recruit non-English speaking individuals for this pilot study.
  8. * Prisoners

Contacts and Locations

Study Contact

Emanual Maverakis, MD
CONTACT
916-734-8254
emaverakis@ucdavis.edu
Lauren Downing
CONTACT
916-551-2635
ldowning@ucdavis.edu

Principal Investigator

Emanual Maverakis, MD
PRINCIPAL_INVESTIGATOR
UC Davis

Study Locations (Sites)

University of California, Davis, Department of Dermatology
Sacramento, California, 95816
United States

Collaborators and Investigators

Sponsor: University of California, Davis

  • Emanual Maverakis, MD, PRINCIPAL_INVESTIGATOR, UC Davis

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2013-01-28
Study Completion Date2026-09-28

Study Record Updates

Study Start Date2013-01-28
Study Completion Date2026-09-28

Terms related to this study

Keywords Provided by Researchers

  • Human microbiome
  • Topical
  • Steroid
  • Anti-fungal

Additional Relevant MeSH Terms

  • Healthy